Latin America Breast Cancer Therapeutics Market Report 2022 to 2030

Latin America Breast Cancer Therapeutics Market Analysis

$ 3999

The Latin America breast cancer therapeutics market is expected to grow from $0.81 Bn in 2022 to $2.32 Bn in 2030 with a CAGR of 13.9% for the forecasted year 2022-2030. The increasing prevalence of breast cancer and rising public awareness about the available therapies and advancements are the major market drivers in the Latin America breast cancer therapeutics market. The market is segmented by therapy, by cancer type, and by distribution channel. Medley Genomics, Eurofarma Laboratrios, and Ach Laboratrios Farmacuticos are some of the key players in the Latin America breast cancer therapeutics market.

ID: IN10LAPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: Latin America AUTHOR: Parul Choudhary

Buy Now

Latin America Breast Cancer Therapeutics Market Executive Analysis

The Latin America breast cancer therapeutics market size is at around $0.81 Bn in 2022 and is projected to reach $2.32 Bn in 2030, exhibiting a CAGR of 13.9% during the forecast period. Chile had the greatest obligatory health spending per capita among the countries we evaluated in 2020, coming in at around $1,572 per person. Following Costa Rica, which spent over $1,231 per person on healthcare, Mexico spent only about $649 per person on healthcare. Among a few Latin American nations, the North American nation has the lowest total health spending per capita. Most Latin American nations' health policies have been reformed with the specific goals of boosting access, reducing inequality, and offering financial security. In essence, the Universal Health Coverage (UHC) model and the Single Universal Health System model of reform have been put into place.

In Latin America, breast cancer is the most prevalent type of cancer among women. An estimated 115,000 women are diagnosed with breast cancer every year, and 37,000 of them pass away from the disease. Both incidence and mortality rates are rising, unlike in Europe or the US, and mortality is projected to double in less than 20 years. The primary risk factor for breast cancer is considered to be ageing; as one gets older, the likelihood of developing breast cancer rises sharply. All systemic treatments used in medical therapy are authorized, although the usage of some very effective medicines is restricted due to financial constraints. Adjuvant chemotherapy lowers the relative risk of death each year by 20% for women aged 50 to 69 and by roughly 40% for those under the age of 50. More than 30% of the relative risk of mortality is reduced in women with oestrogen receptor-positive illness who are receiving tamoxifen hormone therapy. A year of trastuzumab adjuvant therapy reduces the chance of recurrence in women with HER2-positive breast cancer by 50%. The use of contemporary medications varies substantially by country and insurance type. Tamoxifen and anthracycline chemotherapy are both commonly used to treat patients with malignancies that express the oestrogen receptor. Trastuzumab and other biologic therapies like aromatase inhibitors are examples of newer hormonal medications, although not many women can afford them.

latin america breast cancer therapeutics market

Market Dynamics

Market Growth Drivers

The Latin America breast cancer therapeutics market is growing as a result of an increase in the prevalence of breast cancer, population growth, more disposable income among the older population, and greater public awareness of available therapies and medical advancements. The development of biological and targeted therapies and personalised medications has advanced cancer drug research, opening up exciting opportunities for pharmaceutical firms working in the field.

Market Restraints

Latin America's breast cancer therapeutics market growth is hampered by the high cost of new therapeutic research, failure risk, and unfavourable side effects of anti-cancer potential therapies.

Competitive Landscape

Key Players

Novartis
F. Hoffmann-La Roche
Medley Genomics
Eurofarma Laboratrios
Ach Laboratrios Farmacuticos
Laboratories
Laboratrio Cristlia

Healthcare Policies and Regulatory Landscape

Access to breast cancer treatment varies greatly across Latin America, primarily due to the type of insurance and the region's location. The economy of the region and the desire to invest in breast cancer care can have a significant impact on access, even within the same insurance type or nation. For instance, depending on the type of insurance, Brazil allocates varying amounts of resources to the treatment of breast cancer. The Compulsory Medical Plan in Argentina provides 100% public coverage for oncology medications. Geographic inequalities arise as a result of the differing types and standards of treatments offered in various provinces or districts. In contrast, 64% of people in Peru rely on state health insurance, which only covers the diagnosis of breast cancer and not its treatment.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.